15 Prozent der zwischen 1995 und 1999 neu gegründeten Biotechnologieunternehmen erhielten Venture Capital (VC). Am begehrtesten waren Medikamenten- und Wirkstoffentwickler sowie Dienstleister im Bereich medizinischer Anwendungen. Hier wurde nahezu jedes dritte Unternehmen mit VC finanziert.

Auch im Ruhrgebiet sind Anzeichen einer regionalen Häufung von Biotechnologie-Gründern zu beobachten. In qualitativer Hinsicht ist das Ruhrgebiet wenig attraktiv für Gründer aus anderen Regionen und solchen mit hohem Innovationspotenzial. Das Ruhrgebiet hat bisher keine einzige...

We answer the questions, how many firms acting in the modern German biotechnology industry are funded by venture capital companies (VCC) as well as equity funded by corporate investors. The theory suggests a high relevance of VCC as venturing partner of high-tech projects. In addition we argue...

The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make different efforts to overcome shortcomings and recent gaps. Public funding schemes have been implemented to establish a flourish biotech industry in Germany. We assume that R&D policy...

The paper tests empirically the role of knowledge stocks to explain the regional distribution of Germany’s biotechnology founders. We present an unique approach to highlight the role of knowledge spillovers as we differentiate according the local embeddedness and research affinity of founders....

Regions with biotechnology-specific knowledge seem to have best chances to attract potential entrepreneurs to establish a biotechnology-firm. Furthermore, regional oriented technology policy is supposed to stimulate the creation process of biotechnology clusters, too. The BioRegio contest (BRC)...